Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Supplemental material
  • Version history
  • Article usage
  • Citations to this article

Advertisement

ResearchIn-Press PreviewCell biologyNeuroscience Open Access | 10.1172/JCI193407

Aggregation shifts amyloid-β peptides from synaptogenic to synaptotoxic

Alberto Siddu,1 Silvia Natale,2 Connie H. Wong,2 Hamidreza Shaye,2 and Thomas C. Südhof1

1Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

2Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

Find articles by Siddu, A. in: PubMed | Google Scholar

1Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

2Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

Find articles by Natale, S. in: PubMed | Google Scholar

1Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

2Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

Find articles by Wong, C. in: PubMed | Google Scholar

1Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

2Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

Find articles by Shaye, H. in: PubMed | Google Scholar

1Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

2Dept. of Molecular and Cellular Physiology, Stanford University School of Medicine, Stanford, United States of America

Find articles by Südhof, T. in: PubMed | Google Scholar

Published September 30, 2025 - More info

J Clin Invest. https://doi.org/10.1172/JCI193407.
Copyright © 2025, Siddu et al. This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Published September 30, 2025 - Version history
View PDF
Abstract

Whether amyloid-β (Aβ) peptides are synaptogenic or synaptotoxic remains a pivotal open question in Alzheimer’s disease research. Here, we chronically treated human neurons with precisely controlled concentrations of chemically defined synthetic Aβ40, Aβ42, and Aβ42arctic peptides that exhibit distinct aggregation propensities. Remarkably, chronic exposure of human neurons to free Aβ40 at higher concentrations or to free Aβ42 at lower concentrations potently promoted synapse formation. In contrast, aggregated Aβ42 or Aβ42arctic at higher concentrations were neurotoxic and synaptotoxic. The synaptotoxic effects of Aβ peptides manifested as an initial contraction of the synaptic vesicle cluster followed by synapse loss. Aβ40 and Aβ42 peptides with scrambled or inverted sequences were inactive. Thus, our experiments reveal that Aβ peptides exhibit an aggregation-dependent functional dichotomy that renders them either synaptogenic or synaptotoxic, thereby providing insight into how Aβ peptides straddle a thin line between physiological synapse organization and pathological synapse disruption. Among others, our data suggest that Alzheimer’s disease therapies might aim to shift the balance of Aβ peptides from the aggregated to the free state instead of suppressing all Aβ peptides.

Supplemental material

View Unedited blot and gel images

View Mass spectrometry Ab peptides used in the study

Version history
  • Version 1 (September 30, 2025): In-Press Preview

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Supplemental material
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts